Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy
Biogen on Thursday mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the company’s head of research and development releasing an open letter to the Alzheimer’s community that took direct aim at critics of approval.
Al Sandrock, the R&D chief and an architect of many of Biogen’s successes, wrote that the purpose of the letter was to correct “misinformation” about the drug.
